Drug intelligence / Profile preview

AZD8965

Development stage: Phase 2
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

AZD8965 is a small molecule arginase inhibitor developed by AstraZeneca for the treatment of idiopathic pulmonary fibrosis (IPF). As an arginase inhibitor, it targets the enzyme arginase, which plays a role in the metabolism of L-arginine and is implicated in fibrotic processes. By inhibiting arginase activity, AZD8965 aims to reduce fibrosis and improve outcomes in IPF. The drug is currently undergoing phase I clinical trials to assess its safety, tolerability, and pharmacokinetics following single and multiple ascending oral doses in healthy participants[2][3][7].

Other names: AZD 8965AZD8965AZD-8965

Targets

ARG1 (Arginase 1)

Beyond the preview

Go deeper on AZD8965.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZD8965.

Explore the full profile